...Expected 2023 Milestones with its Lead Asset BNC210 - Bio...
Postmarket research Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts December 17, 2024 · 2 min read · Tristan Manalac Pipeline Merck Axes Two Cancer Candidates...